Actively Recruiting
Safety and Impact of Broadly Neutralizing Antibodies Combined With Therapeutic Vaccination in People With Acute HIV Infection
Led by Henry M. Jackson Foundation for the Advancement of Military Medicine · Updated on 2026-09-04
48
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a phase I, randomized, double-blind, placebo-controlled clinical trial to study the safety of two broadly neutralizing antibodies, VRC07-523LS and PGDM1400LS, combined with several therapeutic HIV vaccines in people living with HIV-1 who started antiretroviral therapy ART during acute infection. The study aims to evaluate the effects on viral load setpoint during an analytic treatment interruption ATI. Participants are divided into three groups Group 1 receives the antibodies and a series of vaccines, Group 2 receives the antibodies and placebo vaccinations, and Group 3 consists of newly diagnosed participants who have not yet started ART and receive the antibodies and vaccines on a different schedule. Treatments include antibody infusions, ART initiation or continuation, and multiple vaccine doses administered at specified weeks across the study timeline. Throughout the study, participants undergo regular monitoring including blood tests to measure viral load, immune cell counts, and antibody levels. Researchers also assess neurological and cognitive functions and monitor safety from enrollment up to 100 weeks. Participants will interrupt and restart ART under study supervision, with close follow-up to track viral rebound and immune responses during and after ATI.
CONDITIONS
Brief Title
RV630 - Approach to Control HIV With Immune Enhancement and Vaccination (ACHIEV
Research Team
K
Kiat Ruxrungtham, MD
D
Donn Colby, MD, MPH
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here